B. Melosky

553 total citations
22 papers, 433 citations indexed

About

B. Melosky is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, B. Melosky has authored 22 papers receiving a total of 433 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Hematology. Recurrent topics in B. Melosky's work include Lung Cancer Treatments and Mutations (8 papers), Erythropoietin and Anemia Treatment (4 papers) and Lung Cancer Diagnosis and Treatment (4 papers). B. Melosky is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Erythropoietin and Anemia Treatment (4 papers) and Lung Cancer Diagnosis and Treatment (4 papers). B. Melosky collaborates with scholars based in Canada, United States and Italy. B. Melosky's co-authors include Mario E. Lacouture, Karen A. Gelmon, Stephen Chia, Helen McTaggart‐Cowan, Stuart Peacock, Paulos Teckle, Norma J. Hudon, L.D. Mayer, Marcel B. Bally and Pip Logan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Journal of the American Society of Nephrology.

In The Last Decade

B. Melosky

19 papers receiving 423 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B. Melosky Canada 9 210 137 68 64 48 22 433
Gina Villani United States 10 214 1.0× 133 1.0× 67 1.0× 25 0.4× 38 0.8× 24 456
Lee Schwartzberg United States 8 333 1.6× 133 1.0× 113 1.7× 104 1.6× 21 0.4× 17 603
Olumide B. Gbolahan United States 18 312 1.5× 179 1.3× 118 1.7× 63 1.0× 30 0.6× 65 766
Burkhard Otremba Germany 11 234 1.1× 133 1.0× 43 0.6× 19 0.3× 188 3.9× 41 590
Thuan V. Tran Vietnam 11 168 0.8× 90 0.7× 81 1.2× 23 0.4× 94 2.0× 24 474
Ruta Rao United States 13 307 1.5× 161 1.2× 59 0.9× 20 0.3× 13 0.3× 46 567
A. Pronk Netherlands 17 312 1.5× 86 0.6× 83 1.2× 18 0.3× 8 0.2× 29 608
Jules L.L.M. Coenen Netherlands 12 195 0.9× 261 1.9× 52 0.8× 29 0.5× 75 1.6× 20 469
K C Lakshmaiah India 11 315 1.5× 186 1.4× 105 1.5× 25 0.4× 26 0.5× 28 544
Kristian Aabo Denmark 13 282 1.3× 152 1.1× 81 1.2× 18 0.3× 58 1.2× 38 694

Countries citing papers authored by B. Melosky

Since Specialization
Citations

This map shows the geographic impact of B. Melosky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Melosky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Melosky more than expected).

Fields of papers citing papers by B. Melosky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Melosky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Melosky. The network helps show where B. Melosky may publish in the future.

Co-authorship network of co-authors of B. Melosky

This figure shows the co-authorship network connecting the top 25 collaborators of B. Melosky. A scholar is included among the top collaborators of B. Melosky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Melosky. B. Melosky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Melosky, B., Eckart Laack, Kato Kambartel, et al.. (2021). P37.17 Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutations in Non-small Cell Lung Cancer (NSCLC): A Global Meta-analysis. Journal of Thoracic Oncology. 16(3). S449–S449. 1 indexed citations
2.
Hao, Desirée, Janessa Laskin, Scott A. Laurie, et al.. (2021). P89.03 Demonstrating VALUE of Liquid Biopsy for Lung Cancer in a Public Healthcare System. Journal of Thoracic Oncology. 16(3). S689–S689. 6 indexed citations
3.
Laurie, Scott A., Jason Agulnik, Desirée Hao, et al.. (2020). 1195P The value of detecting resistance through liquid biopsy. Annals of Oncology. 31. S786–S787. 1 indexed citations
4.
Berthelet, Eric, et al.. (2020). 1247P Uptake of durvalumab in the management of stage III NSCLC: The real-world application of PACIFIC. Annals of Oncology. 31. S807–S808. 2 indexed citations
5.
Melosky, B., et al.. (2017). Challenging the Paradigm: EGFR wild-type benefit from an EGFR inhibitor in NSCLC. Cancer Treatment and Research Communications. 11. 10–16.
6.
Noonan, Krista, Janessa Laskin, Yulong Zheng, et al.. (2015). Evaluation of a ‘Watch and Wait’ Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population. Clinical Oncology. 27(9). 505–513. 4 indexed citations
7.
Bormanis, Janis, Ian Quirt, José Chang, et al.. (2013). Erythropoiesis-stimulating agents (ESAs): Do they still have a role in chemotherapy-induced anemia (CIA)?. Critical Reviews in Oncology/Hematology. 87(2). 132–139. 7 indexed citations
8.
Teckle, Paulos, Helen McTaggart‐Cowan, Stephen Chia, et al.. (2013). Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D. Health and Quality of Life Outcomes. 11(1). 203–203. 39 indexed citations
9.
Karam, Irene & B. Melosky. (2012). Response to Second-Line Erlotinib in an EGFR Mutation-Negative Patient with Non-Small-Cell Lung Cancer: Make No Assumptions. Current Oncology. 19(1). 42–46. 3 indexed citations
10.
Teckle, Paulos, Stuart Peacock, Helen McTaggart‐Cowan, et al.. (2011). The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities. Health and Quality of Life Outcomes. 9(1). 106–106. 49 indexed citations
11.
Ellis, Peter, Normand Blais, Diana N. Ionescu, et al.. (2011). A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(8). 1379–1391. 76 indexed citations
12.
Teckle, Paulos, et al.. (2011). QA2 CROSS-WALKING CANCER-SPECIFIC INSTRUMENTS TO THE EQ-5D AND SF-6D. Value in Health. 14(3). A11–A11. 1 indexed citations
13.
Melosky, B.. (2008). Erythropoiesis-Stimulating Agents: Benefits and Risks in Supportive Care of Cancer. Current Oncology. 15(11). 10–15. 10 indexed citations
14.
15.
Lacouture, Mario E. & B. Melosky. (2007). Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.. PubMed. 12(6). 1–5. 64 indexed citations
16.
17.
Taylor, S G, et al.. (2005). Anemia and FOLFOX chemotherapy for colorectal carcinoma. Journal of Clinical Oncology. 23(16_suppl). 3684–3684. 1 indexed citations
18.
19.
Gelmon, Karen A., Marcel B. Bally, Leanne Embree, et al.. (1999). Phase I Study of Liposomal Vincristine. Journal of Clinical Oncology. 17(2). 697–697. 91 indexed citations
20.
Paty, Breay W., et al.. (1996). Colonic Carcinoma in Two Adult Cystic Fibrosis Patients. SHILAP Revista de lepidopterología. 10(7). 440–442. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gina Villani Breakdown of academic impact, for papers by Lee Schwartzberg Breakdown of academic impact, for papers by Olumide B. Gbolahan Breakdown of academic impact, for papers by Burkhard Otremba Breakdown of academic impact, for papers by Thuan V. Tran Breakdown of academic impact, for papers by Ruta Rao Breakdown of academic impact, for papers by A. Pronk Breakdown of academic impact, for papers by Jules L.L.M. Coenen Breakdown of academic impact, for papers by K C Lakshmaiah Breakdown of academic impact, for papers by Kristian Aabo
Rankless by CCL
2026